Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready
Greffex Inc. currently faces 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. The prosecution of these matters involves 6 distinct examiners and is spread across 6 distinct art units. This high ratio of art units to pending actions suggests a diverse range of biological or pharmaceutical innovations that do not fall under a single specialized group at the patent office. With several examiners involved, the company must manage different examination styles simultaneously.
SPENCER, ANDREA LYNNE MORRIS is the busiest examiner for this portfolio, holding 2 pending office actions. This examiner is the only individual managing more than a single case, as the remaining pending office actions are distributed among the other distinct examiners. The concentration of 2 pending office actions with this examiner provides a small point of consolidation in an otherwise fragmented prosecution landscape across the various art units. Success in the Biotechnology & Pharmaceuticals area for Greffex Inc. will depend on addressing the specific concerns of these individuals.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §103 only | 3 (43%) |
| §102 only | 1 (14%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPENCER, ANDREA LYNNE MORRIS | 2 | 22.2% | +35.7% |
| MATALKAH, FATIMAH KHALAF | 1 | 54.8% | +28.6% |
| LI, BAO Q | 1 | 75.4% | +26.8% |
| XIAO, YAN | 1 | 67.3% | +52.7% |
| SALVOZA, M FRANCO G | 1 | 68.4% | +30.0% |
| GU, QINHUA | 1 | 75.9% | +27.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17996727 | ENGINEERING BROADLY REACTIVE CORONAVIRUS VACCINES AND RELATED DESIGNS AND USES | SALVOZA, M FRANCO G | — |
| 17995128 | ENHANCEMENT OF THE PRODUCTION OF ADENOVIRUS-BASED GENE TRANSFER VECTORS | SPENCER, ANDREA LYNNE MORRIS | — |
| 17758077 | CULTURE SYSTEMS FOR THE EFFICIENT PRODUCTION OF GENE TRANSFER VECTORS | SPENCER, ANDREA LYNNE MORRIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18252790 | DESIGN OF OPTIMIZED UNIVERSAL INFLUENZA VACCINES, THEIR DESIGNS AND USES | LI, BAO Q | 84d overdue |
| 18264104 | GENE THERAPY FOR RETINAL DISEASES | MATALKAH, FATIMAH KHALAF | — |
| 18025684 | ANTIBODY CONSTRUCTS TO TARGET T CELL RESPONSES TO SARS-COV PROTEIN EXPRESSING CELLS, THEIR DESIGN AND USES | XIAO, YAN | — |
| 17996727 | ENGINEERING BROADLY REACTIVE CORONAVIRUS VACCINES AND RELATED DESIGNS AND USES | SALVOZA, M FRANCO G | — |
| 17995128 | ENHANCEMENT OF THE PRODUCTION OF ADENOVIRUS-BASED GENE TRANSFER VECTORS | SPENCER, ANDREA LYNNE MORRIS | — |
| 17907571 | MAINTAINING DNA FRAGMENTS IN EUKARYOTIC CELLS, APPROACHES AND USES | GU, QINHUA | — |
| 17758077 | CULTURE SYSTEMS FOR THE EFFICIENT PRODUCTION OF GENE TRANSFER VECTORS | SPENCER, ANDREA LYNNE MORRIS | — |
| Art Unit | Apps |
|---|---|
| 1631 | 2 |
| 1638 | 1 |
| 1671 | 1 |
| 1642 | 1 |
| 1672 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18264104 | GENE THERAPY FOR RETINAL DISEASES | MATALKAH, FATIMAH KHALAF | 1638 | §103 | Non-Final OA | — | Pending | Aug 03, 2023 |
| 18252790 | DESIGN OF OPTIMIZED UNIVERSAL INFLUENZA VACCINES, THEIR DESIGNS AND USES | LI, BAO Q | 1671 | §102 | Final Rejection | 84d overdue | Pending | May 12, 2023 |
| 18025684 | ANTIBODY CONSTRUCTS TO TARGET T CELL RESPONSES TO SARS-COV PROTEIN EXPRESSING CELLS, THEIR DESIGN AND USES | XIAO, YAN | 1642 | §102§103§112DP | Non-Final OA | — | Pending | Mar 10, 2023 |
| 17996727 | ENGINEERING BROADLY REACTIVE CORONAVIRUS VACCINES AND RELATED DESIGNS AND USES | SALVOZA, M FRANCO G | 1672 | §101§102§103§112Other | Final Rejection | — | Pending | Oct 20, 2022 |
| 17995128 | ENHANCEMENT OF THE PRODUCTION OF ADENOVIRUS-BASED GENE TRANSFER VECTORS | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103 | Final Rejection | — | Pending | Sep 30, 2022 |
| 17907571 | MAINTAINING DNA FRAGMENTS IN EUKARYOTIC CELLS, APPROACHES AND USES | GU, QINHUA | 1633 | §103 | Final Rejection | — | Pending | Sep 28, 2022 |
| 17758077 | CULTURE SYSTEMS FOR THE EFFICIENT PRODUCTION OF GENE TRANSFER VECTORS | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103§112 | Final Rejection | — | Pending | Jun 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial